Esperion Therapeutics
ESPR
ESPR was delisted on the 10th of July, 2026.
156 hedge funds and large institutions have $1.21B invested in Esperion Therapeutics in 2018 Q2 according to their latest regulatory filings, with 22 funds opening new positions, 67 increasing their positions, 45 reducing their positions, and 52 closing their positions.
49% more repeat investments, than reductions
Existing positions increased: 67 | Existing positions reduced: 45
15.22% more ownership
Funds ownership: 100% → 115.22% (+15%)
17% less funds holding
Funds holding: 187 → 156 (-31)
37% less capital invested
Capital invested by funds: $1.92B → $1.21B (-$706M)
43% less funds holding in top 10
Funds holding in top 10: 7 → 4 (-3)
58% less first-time investments, than exits
New positions opened: 22 | Existing positions closed: 52
76% less call options, than puts
Call options by funds: $25M | Put options by funds: $105M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PHS
PFM Health Sciences
San Francisco,
California
|
+$67.2M |
| 2 |
AH
Aviva Holdings
New Providence,
Bahamas
|
+$52.2M |
| 3 |
State Street
Boston,
Massachusetts
|
+$43.4M |
| 4 |
BB
BB Biotech
Schaffhausen,
Switzerland
|
+$38.9M |
| 5 |
BC
Boxer Capital
San Diego,
California
|
+$24M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$40.5M |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$22.3M |
| 3 |
PA
Pinnacle Associates
New York
|
-$20.6M |
| 4 |
CCI
Columbus Circle Investors
|
-$18.4M |
| 5 |
Caisse de Depot et Placement du Quebec (CDPQ)
Montreal,
Quebec, Canada
|
-$18.1M |
ESPR Hedge Fund Activity: Q2 2018 in Review
156 of the 4,385 institutional investors tracked by Wall St. Rank reported a position in Esperion Therapeutics (ESPR) for Q2 2018, worth a combined $1.21B — down 37% from $1.92B a quarter earlier.
Sellers outnumbered buyers: 52 funds closed out of ESPR and 22 opened new positions — a net loss of 30 holders — while 45 trimmed existing stakes and 67 added.
The largest buyer was PFM Health Sciences, adding an estimated $67.2M. The largest seller was Fidelity Investments, cutting an estimated $40.5M.
- 156 institutional investors held Esperion Therapeutics (ESPR) as of Q2 2018, down from 187 in Q1 2018.
- Funds reported $1.21B of Esperion Therapeutics stock for Q2 2018, down 37% quarter-over-quarter.
- 22 funds opened new Esperion Therapeutics positions in Q2 2018 and 52 closed out, a net change of -30 holders.
- The largest Esperion Therapeutics buyer in Q2 2018 was PFM Health Sciences, an estimated $67.2M added.
- The largest Esperion Therapeutics seller in Q2 2018 was Fidelity Investments, an estimated $40.5M sold.
Based on aggregated 13F filings for Q2 2018.